| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1473-3099(13)70046-X |
| P698 | PubMed publication ID | 23518156 |
| P50 | author | Jeanne-Marie Devaster | Q91991389 |
| Lidia Oostvogels | Q92484261 | ||
| Janet E McElhaney | Q92876176 | ||
| Sharon E Frey | Q109938704 | ||
| Gerrit Adrianus van Essen | Q112409277 | ||
| Meral Esen | Q114402790 | ||
| Florence Galtier | Q114781834 | ||
| Andrew Trofa | Q114781837 | ||
| Influence65 study group | Q114781838 | ||
| Bruce L. Innis | Q39447629 | ||
| Geert Leroux-Roels | Q45380570 | ||
| Peter Gottfried Kremsner | Q50345544 | ||
| Shelly A McNeil | Q56433319 | ||
| Odile Launay | Q65089382 | ||
| Jan Hendrik Richardus | Q88812594 | ||
| Shinn-Jang Hwang | Q88952505 | ||
| Christelle M Durand | Q89642185 | ||
| Ann R Falsey | Q91075894 | ||
| Gregory J Feldman | Q91788032 | ||
| P2093 | author name string | Jiri Beran | |
| Xavier Duval | |||
| Adrian Caplanusi | |||
| Mohamed El Idrissi | |||
| Guillermo M Ruiz-Palacios | |||
| Carine Claeys | |||
| Andrzej Nowakowski | |||
| Martina Kovac | |||
| P2860 | cites work | Vaccines for preventing influenza in healthy adults | Q24234114 |
| Vaccines for preventing influenza in the elderly | Q24245325 | ||
| Vaccines for preventing influenza in healthy adults | Q24245429 | ||
| Induction of lupus autoantibodies by adjuvants | Q28191265 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 | ||
| Influenza-associated hospitalizations in the United States | Q29619463 | ||
| Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. | Q30363500 | ||
| Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. | Q30383903 | ||
| AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. | Q30392336 | ||
| MF59™ as a vaccine adjuvant: a review of safety and immunogenicity | Q30394545 | ||
| Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study | Q30403078 | ||
| Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis | Q30408691 | ||
| Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. | Q30412748 | ||
| Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008 | Q33931144 | ||
| Effectiveness of influenza vaccine in the community-dwelling elderly | Q34007308 | ||
| Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977 | Q34215590 | ||
| Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. | Q34326653 | ||
| The burden of community-acquired pneumonia in seniors: results of a population-based study | Q34373295 | ||
| Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults | Q34764409 | ||
| Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains | Q36854011 | ||
| The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review | Q37352531 | ||
| Epidemiology of giant cell arteritis and polymyalgia rheumatica | Q37605653 | ||
| Polymyalgia rheumatica prevalence in a population-based sample | Q39898622 | ||
| Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial | Q40306076 | ||
| Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study | Q45734830 | ||
| Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study | Q48032303 | ||
| Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. | Q50801938 | ||
| Guillain-Barré Syndrome and the 1978–1979 Influenza Vaccine | Q70771999 | ||
| Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up | Q73816676 | ||
| P433 | issue | 6 | |
| P921 | main subject | influenza vaccine | Q383260 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 485-496 | |
| P577 | publication date | 2013-03-19 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial | |
| P478 | volume | 13 |
| Q89186695 | A clinically applicable adjuvant for an atherosclerosis vaccine in mice |
| Q97680700 | A global agenda for older adult immunization in the COVID-19 era: A roadmap for action |
| Q89050585 | A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults |
| Q30370147 | A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. |
| Q42269932 | AS03-adjuvanted influenza vaccine in elderly people |
| Q42195604 | Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines |
| Q38140045 | Adjuvanted influenza vaccines |
| Q30352329 | An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. |
| Q92264645 | Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines |
| Q38636645 | B Cell-Specific Biomarkers for Optimal Antibody Responses to Influenza Vaccination and Molecular Pathways That Reduce B Cell Function with Aging |
| Q56772813 | Bupivacaine enhances the magnitude and longevity of HIV-specific immune response after immunization with a CD4 epitope-based DNA vaccine |
| Q40151447 | Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison |
| Q40280177 | Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014. |
| Q30891396 | Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis |
| Q39012223 | Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects |
| Q38852557 | Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial |
| Q40478812 | Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status. |
| Q40064119 | Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans |
| Q28073431 | Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis |
| Q38998621 | Fluzone® High-Dose Influenza Vaccine. |
| Q37643313 | Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial |
| Q37061098 | Harnessing the beneficial heterologous effects of vaccination |
| Q35837747 | Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease |
| Q30362521 | High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. |
| Q40968370 | Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial |
| Q37560954 | Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis |
| Q36962721 | Immunosenescence and novel vaccination strategies for the elderly. |
| Q47128858 | Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains |
| Q91842085 | Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals |
| Q38602985 | Influenza and other respiratory virus infections in solid organ transplant recipients |
| Q34274845 | Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines |
| Q42814278 | Influenza vaccination and the end of simplicity |
| Q40134515 | Influenza vaccination in the elderly. |
| Q34505958 | Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain |
| Q40997493 | Influenza vaccine efficacy trials: a simulation approach to understand failures from the past |
| Q24188037 | Influenza vaccines for preventing cardiovascular disease |
| Q37518273 | Influenza vaccines: unmet needs and recent developments |
| Q30388063 | Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis. |
| Q36367842 | Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis |
| Q30352104 | Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. |
| Q89723360 | Next-generation influenza vaccines: opportunities and challenges |
| Q30372260 | Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. |
| Q64375019 | Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults |
| Q92711478 | Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis |
| Q60044730 | Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults |
| Q90214218 | Precision immunization: a new trend in human vaccination |
| Q41089501 | Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines |
| Q30360483 | Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. |
| Q47340934 | Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. |
| Q38979133 | Reporting of pre-enrolment screening with randomized clinical trials: A small item that could impact a big difference |
| Q33684340 | Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness |
| Q35887417 | Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial |
| Q91577533 | Safety of AS03-adjuvanted influenza vaccines: A review of the evidence |
| Q37694883 | Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison |
| Q30387979 | Seasonal influenza vaccination of high-risk adults |
| Q34869353 | Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial |
| Q90669095 | Short-term and mid-term solutions for influenza vaccines |
| Q39193878 | Successful and Maladaptive T Cell Aging |
| Q34067461 | Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. |
| Q88642245 | Sustainable vaccine development: a vaccine manufacturer's perspective |
| Q26768539 | T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines |
| Q60301819 | Technologies to address antimicrobial resistance |
| Q87232318 | The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly |
| Q40784710 | The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations |
| Q37635329 | The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial |
| Q94601820 | The immune response to influenza in older humans: beyond immune senescence |
| Q38871207 | The life cycle of a T cell after vaccination - where does immune ageing strike? |
| Q26773027 | The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper |
| Q111441839 | The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination |
| Q41299004 | Transmission and effect of multiple clusters of seasonal influenza in a Swiss geriatric hospital |
| Q41934895 | Vaccine approaches conferring cross-protection against influenza viruses |
| Q37179398 | Vaccine strategies to enhance immune responses in the aged |
Search more.